PORTOLA PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Net loss
Operating activities
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization
Amortization of operating lease right-of-use assets
Accretion of discount on investment securities
Non-cash interest expense
Stock-based compensation expense, net of capitalized labor
Remeasurement loss on embedded derivatives liabilities
Stock-based compensation expense for Lonza liability-classified award
Charge associated with our Gen 1 manufacturing process transition
Remeasurement (gain) loss on embedded derivatives liabilities
Provision for excess and obsolete inventories
Change in reserve for uncertain tax position
Loss on impairment and provision for excess and obsolete inventories of Bevyxxa asset group
Loss on impairment of SRX intangible asset
Others
Changes in operating assets and liabilities:
Inventories
Prepaid research and development
Trade and other receivables, net
Unbilled - collaboration and license revenue
Prepaid and other current assets
Prepaid and other long-term assets
Accounts payable
Accrued compensation and employee benefits
Accrued research and development
Accrued and other liabilities
Deferred revenue
Notes payable, long term debt and long term obligation to collaborator
Notes payable and long term royalty-based debt
Other long-term liabilities

Net cash used in operating activities
Investing activities
Capital expenditures, net
Increase in restricted cash (Development Partner)
Decrease (increase) in restricted cash (SRX Cardio)
Purchase of intangible assets
Purchases of investments
Proceeds from maturities of investments
Proceeds from public offering of common stock, net of underwriters discount
Net cash (used in) provided by investing activities

Financing activities
Proceeds from debt issuance, net
Proceeds from issuance of common stock from public offering, net
Debt issuance costs paid
Payment of public offering costs
Proceeds from issuance of common stock pursuant to equity award plans
Dividends to Noncontrolling interest (SRX Cardio)'s shareholders
Proceeds from long-term notes payable
Proceeds from long-term obligation to Collaborator
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Payments of long-term obligation to collaborator
Other
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Net change in accrued offering cost
Net change in accounts payable related to purchase of property and equipment

Comments